Previous 10 | Next 10 |
SHELTON, CT / ACCESSWIRE / November 28, 2023 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the Single-Ascending Dose part of the Phase 1a/1b Human Cl...
SHELTON, CT / ACCESSWIRE / November 15, 2023 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending September 30, 2023 with the Securities and Exchange Commission (SEC) on Tuesday, November 14,...
SHELTON, CT / ACCESSWIRE / November 14, 2023 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reports that its broad-spectrum antiviral drug candidate, NV-387 was highly effective i...
SHELTON, CT / ACCESSWIRE / October 16, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2023 with the Securities and Exchange Commission (SEC) on Friday, October 13, 2023. The report ca...
SHELTON, CT / ACCESSWIRE / October 12, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the Partnership Opportunities in Drug Delivery (PODD) Conference in Boston, MA, on October 16, ...
(NewsDirect) By David Willey, Benzinga Read the latest report on NanoViricides here The CDC recently issued a warning that Respiratory Syncytial Virus (RSV), a common and highly contagious lung infection that can cause bronchitis and pneumonia, is on the rise in th...
(NewsDirect) Proactive research analyst John Savin speaks to Thomas Warner after publishing a research note about the latest Covid trial from development-stage antiviral company NanoViricides (NYSE-A:NNVC). The ongoing NV-CoV-2 Phase Ia clinical study is a key milestone in the develop...
SHELTON, CT / ACCESSWIRE / August 21, 2023 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Compan...
(NewsDirect) By David Willey, Benzinga Read the latest report on NanoViricides here . SARS-CoV-2 is not done yet — Although it is not grabbing as many headlines, the number of deaths are still greater than even a pandemic influenza year at last count. The virus ...
--News Direct-- By David Willey, Benzinga Read the latest report on NanoViricides here . SARS-CoV-2 is not done yet — Although it is not grabbing as many headlines, the number of deaths are still greater than even a pandemic influenza year at last count. The vir...
News, Short Squeeze, Breakout and More Instantly...
Shares of AMMO, Inc. (NASDAQ:POWW) fell sharply during Friday's session following fourth-quarter results. AMMO reported a fourth-quarter profi...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 1.8% to $131.88 on volume of 307,014,213 shares SRIVARU Holding Limited (SVMH) rose 49.2% to $0.2275 on volume of 274,465,266 shares Nauticus Robotics Inc. (KITT) rose 19.6% to $0.192 on volume of 161,46...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 3.5% to $125.2 on volume of 291,129,456 shares Apple Inc. (AAPL) rose 2.9% to $213.07 on volume of 194,159,376 shares PROSHARES TRUST (SQQQ) fell 3.9% to $8.68 on volume of 178,616,604 shares Golden He...